Overview

A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease

Status:
Recruiting

Trial end date:
2022-11-30

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to evaluate the efficacy and safety of a single intravenous (IV) re-induction dose of approximately 6 milligram per kilogram (mg/kg) ustekinumab in participants with secondary loss of response (LoR) to subcutaneous (SC) every 8 Weeks (q8w) 90 mg ustekinumab maintenance therapy.

Phase:

Phase 3

Details

Lead Sponsor:

Janssen-Cilag Ltd.

Treatments:

Ustekinumab